Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab

BACKGROUND: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life‐threatening autoimmune thrombotic microangiopathy. Current standard of care is therapeutic plasma exchange, immunosuppression, and caplacizumab, an anti‐von Willebrand factor nanobody, which is effective in treating aTTP...

Descripción completa

Detalles Bibliográficos
Autores principales: Völker, Linus A., Brinkkoetter, Paul T., Knöbl, Paul N., Krstic, Miroslav, Kaufeld, Jessica, Menne, Jan, Buxhofer‐Ausch, Veronika, Miesbach, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
PLATELETS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692904/
https://www.ncbi.nlm.nih.gov/pubmed/32757435
http://dx.doi.org/10.1111/jth.15045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692904/
https://www.ncbi.nlm.nih.gov/pubmed/32757435
http://dx.doi.org/10.1111/jth.15045

Ejemplares similares